Trump confirms Makary out at FDA
President Donald Trump confirmed on Tuesday that Marty Makary would be leaving his post atop the U.S. Food and Drug Administration.
While speaking to reporters on the White House lawn Tuesday, Trump said Makary would be leaving. He said FDA deputy commissioner Kyle Diamantes will take over as the adminsitration seeks a new leader of the federal agency.
“He was having some difficulty,” Trump said. “Marty is a terrific guy, but he’s going to go and lead a good life.”
Trump did not specify what kind of difficulty Makary experienced. Several reports circulated that there was an internal dispute over approval for flavored vapes at the FDA. The Wall Street Journal reported that Trump pressured Makary to approve fruit-flavored vapes, but he was hesitant to do so.
Trump said many people are seeking the job atop the agency.
Makary was expected to testify on Capitol Hill Wednesday to present the FDA’s budget for the upcoming fiscal year. Diamantes is expected to take his place.
Makary was confirmed to lead the FDA in March 2025. Since then, he’s sought to make several changes to the agency’s policies and change organizational structure. Makary sought to limit antidepressants for pregnant women and ban kratom byproducts.
“He’s a friend of mine, he’s a wonderful man and he’s going to be off,” Trump said of Makary.
Latest News Stories
Service member killed in action; remains found in search for one missing
Second family welcomes baby boy
Everyday Economics: Falling gas prices helped keep consumers spending
Illinois may bring early warning of toll costs ahead of proposed rate hike
Illinois senator says True Value move highlights business climate concerns
Two services members killed, one missing in Iranian strike
U.S. Coast Guard monitors Chinese ships off Alaska coast
Millions celebrate America 250, Sail250 events in key ports
Chicago delays vote on parking meter sale, risks litigation
Hegseth’s ‘High-T’ troop screening mandate comes without cost estimate
Congressional candidates tackle housing, immigration
Senators to examine hospital price transparency legislation